Does the media favor ANIK or RNTX?

In the previous week, Rein Therapeutics had 12 more articles in the media than Anika Therapeutics. MarketBeat recorded 14 mentions for Rein Therapeutics and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.84 beat Rein Therapeutics' score of 0.19 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anika Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, ELDN or RNTX?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.91 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is ELDN or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% Rein Therapeutics N/A N/A -63.69%

Does the media favor ELDN or RNTX?

In the previous week, Rein Therapeutics had 12 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 14 mentions for Rein Therapeutics and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Rein Therapeutics' score of 0.19 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SRZN or RNTX more profitable?

Rein Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%. Company Net Margins Return on Equity Return on Assets Surrozen -2,885.33% N/A -93.62% Rein Therapeutics N/A N/A -63.69%

Does the media favor SRZN or RNTX?

In the previous week, Rein Therapeutics had 11 more articles in the media than Surrozen. MarketBeat recorded 14 mentions for Rein Therapeutics and 3 mentions for Surrozen. Surrozen's average media sentiment score of 0.33 beat Rein Therapeutics' score of 0.19 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rein Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, RNTX or ALXO?

ALX Oncology is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is RNTX or ALXO more profitable?

Rein Therapeutics' return on equity of 0.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -63.69% ALX Oncology N/A -90.30% -67.28%

Does the media prefer RNTX or ALXO?

In the previous week, Rein Therapeutics had 1 more articles in the media than ALX Oncology. MarketBeat recorded 14 mentions for Rein Therapeutics and 13 mentions for ALX Oncology. Rein Therapeutics' average media sentiment score of 0.19 beat ALX Oncology's score of 0.06 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rein Therapeutics (RNTX) Competitors

$0.82 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Compare

RNTX vs. ANIK, ELDN, SRZN, BCYC, and ALXO

Should you buy Rein Therapeutics stock or one of its competitors? Rein Therapeutics's main competitors and comparable companies include Anika Therapeutics (ANIK), Eledon Pharmaceuticals (ELDN), Surrozen (SRZN), Bicycle Therapeutics (BCYC), and ALX Oncology (ALXO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rein Therapeutics compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Rein Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anika Therapeutics	-3.14%	0.20%	0.15%
Rein Therapeutics	N/A	N/A	-63.69%

Anika Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

Anika Therapeutics presently has a consensus target price of $21.00, indicating a potential downside of 3.58%. Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 633.50%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anika Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 12.1% of Anika Therapeutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anika Therapeutics has higher revenue and earnings than Rein Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anika Therapeutics	$112.82M	2.58	-$10.88M	-$0.27	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

In the previous week, Rein Therapeutics had 12 more articles in the media than Anika Therapeutics. MarketBeat recorded 14 mentions for Rein Therapeutics and 2 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.84 beat Rein Therapeutics' score of 0.19 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anika Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Anika Therapeutics beats Rein Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Rein Therapeutics' return on equity of 0.00% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
Rein Therapeutics	N/A	N/A	-63.69%

Eledon Pharmaceuticals currently has a consensus target price of $9.67, suggesting a potential upside of 180.19%. Rein Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 633.50%. Given Rein Therapeutics' higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eledon Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

In the previous week, Rein Therapeutics had 12 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 14 mentions for Rein Therapeutics and 2 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 1.35 beat Rein Therapeutics' score of 0.19 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Eledon Pharmaceuticals beats Rein Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Rein Therapeutics compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Surrozen currently has a consensus price target of $45.00, indicating a potential upside of 87.58%. Rein Therapeutics has a consensus price target of $6.00, indicating a potential upside of 633.50%. Given Rein Therapeutics' higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Rein Therapeutics has lower revenue, but higher earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$3.48M	80.04	-$242.03M	-$40.55	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rein Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -2,885.33%.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-2,885.33%	N/A	-93.62%
Rein Therapeutics	N/A	N/A	-63.69%

Surrozen has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market.

In the previous week, Rein Therapeutics had 11 more articles in the media than Surrozen. MarketBeat recorded 14 mentions for Rein Therapeutics and 3 mentions for Surrozen. Surrozen's average media sentiment score of 0.33 beat Rein Therapeutics' score of 0.19 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rein Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rein Therapeutics beats Surrozen on 9 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Bicycle Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Rein Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Rein Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

Rein Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

In the previous week, Rein Therapeutics had 14 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 14 mentions for Rein Therapeutics and 0 mentions for Bicycle Therapeutics. Rein Therapeutics' average media sentiment score of 0.19 beat Bicycle Therapeutics' score of 0.00 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rein Therapeutics	Neutral
Bicycle Therapeutics	Neutral

Rein Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 633.50%. Bicycle Therapeutics has a consensus price target of $13.86, indicating a potential upside of 217.10%. Given Rein Therapeutics' higher probable upside, equities analysts clearly believe Rein Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Rein Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
Bicycle Therapeutics	$61.21M	5.00	-$218.96M	-$2.73	N/A

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Rein Therapeutics beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to ALX Oncology?

Rein Therapeutics (NASDAQ:RNTX) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by company insiders. Comparatively, 12.4% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rein Therapeutics' return on equity of 0.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
ALX Oncology	N/A	-90.30%	-67.28%

Rein Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 633.50%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 125.49%. Given Rein Therapeutics' higher possible upside, research analysts clearly believe Rein Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Rein Therapeutics had 1 more articles in the media than ALX Oncology. MarketBeat recorded 14 mentions for Rein Therapeutics and 13 mentions for ALX Oncology. Rein Therapeutics' average media sentiment score of 0.19 beat ALX Oncology's score of 0.06 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rein Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

ALX Oncology is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Summary

Rein Therapeutics beats ALX Oncology on 8 of the 13 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$70.57M	$4.00B	$7.32B	$12.82B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-0.48	11.68	272.91	24.33
Price / Sales	N/A	1,377.87	639.20	97.25
Price / Cash	14.31	44.94	29.03	36.90
Price / Book	-0.76	17.70	11.38	6.42
Net Income	-$49.87M	-$22.72M	$3.47B	$348.89M
7 Day Performance	-2.77%	2.73%	2.16%	0.51%
1 Month Performance	3.37%	9.63%	7.59%	4.84%
1 Year Performance	-35.59%	54.98%	25.16%	17.04%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	3.5725 of 5 stars	$0.82 flat	$6.00 +633.5%	-35.6%	$70.57M	N/A	N/A	9	Analyst Downgrade Gap Down
ANIK Anika Therapeutics	3.3667 of 5 stars	$21.16 -1.6%	$21.00 -0.8%	+125.7%	$283.15M	$112.82M	N/A	300
ELDN Eledon Pharmaceuticals	2.2535 of 5 stars	$3.64 +2.8%	$9.67 +165.6%	+32.7%	$280.97M	N/A	N/A	10	News Coverage Analyst Downgrade
SRZN Surrozen	2.8646 of 5 stars	$23.85 -0.4%	$42.00 +76.1%	+113.8%	$277.65M	$3.48M	N/A	80
BCYC Bicycle Therapeutics	2.4908 of 5 stars	$3.95 +1.3%	$13.86 +250.7%	-38.5%	$276.53M	$72.86M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. ANIK, ELDN, SRZN, BCYC, and ALXO

How does Rein Therapeutics compare to Anika Therapeutics?

Summary

How does Rein Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Rein Therapeutics compare to Surrozen?

Summary

How does Rein Therapeutics compare to Bicycle Therapeutics?

Summary

How does Rein Therapeutics compare to ALX Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. ANIK, ELDN, SRZN, BCYC, and ALXO

How does Rein Therapeutics compare to Anika Therapeutics?

Is ANIK or RNTX more profitable?

Which has more risk and volatility, ANIK or RNTX?

Do analysts recommend ANIK or RNTX?

Do institutionals and insiders have more ownership in ANIK or RNTX?

Which has stronger earnings and valuation, ANIK or RNTX?

Does the media favor ANIK or RNTX?

Summary

How does Rein Therapeutics compare to Eledon Pharmaceuticals?

Is ELDN or RNTX more profitable?

Do analysts prefer ELDN or RNTX?

Do institutionals & insiders hold more shares of ELDN or RNTX?

Which has more volatility and risk, ELDN or RNTX?

Does the media favor ELDN or RNTX?

Which has higher earnings & valuation, ELDN or RNTX?

Summary

How does Rein Therapeutics compare to Surrozen?

Do analysts prefer SRZN or RNTX?

Which has better earnings & valuation, SRZN or RNTX?

Do institutionals & insiders believe in SRZN or RNTX?

Is SRZN or RNTX more profitable?

Which has more volatility and risk, SRZN or RNTX?

Does the media favor SRZN or RNTX?

Summary

How does Rein Therapeutics compare to Bicycle Therapeutics?

Is RNTX or BCYC more profitable?

Which has more risk and volatility, RNTX or BCYC?

Does the media refer more to RNTX or BCYC?

Do analysts recommend RNTX or BCYC?

Which has preferable earnings & valuation, RNTX or BCYC?

Do institutionals and insiders have more ownership in RNTX or BCYC?

Summary

How does Rein Therapeutics compare to ALX Oncology?

Do institutionals & insiders have more ownership in RNTX or ALXO?

Is RNTX or ALXO more profitable?

Do analysts rate RNTX or ALXO?

Does the media prefer RNTX or ALXO?

Which has more volatility and risk, RNTX or ALXO?

Which has higher valuation & earnings, RNTX or ALXO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools